Ayed O Ayed

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3943911/publications.pdf

Version: 2024-02-01

10 papers	229 citations	1307366 7 h-index	1474057 9 g-index
10 all docs	10 docs citations	10 times ranked	630 citing authors

#	Article	IF	Citations
1	Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. Journal of Experimental Medicine, 2018, 215, 681-697.	4.2	65
2	Ruxolitinib as firstâ€line treatment in secondary hemophagocytic lymphohistiocytosis: A second experience. American Journal of Hematology, 2018, 93, E123-E125.	2.0	39
3	Relationship of serum imatinib trough level and response in CML patients: Long term follow-up. Leukemia Research, 2010, 34, 1573-1575.	0.4	36
4	Interobserver Variability of Mitotic Index and Utility of PHH3 for Risk Stratification in Gastrointestinal Stromal Tumors. American Journal of Clinical Pathology, 2015, 143, 385-392.	0.4	28
5	Immunotherapy for multiple myeloma: Current status and future directions. Critical Reviews in Oncology/Hematology, 2015, 96, 399-412.	2.0	25
6	CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies. Blood Cancer Journal, 2018, 8, 63.	2.8	22
7	Frequency, risk factors, and outcomes of central nervous system relapse in lymphoma patients treated with doseâ€adjusted EPOCH plus rituximab. American Journal of Hematology, 2017, 92, 1156-1162.	2.0	8
8	Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy. Leukemia and Lymphoma, 2018, 59, 2287-2296.	0.6	4
9	Lenalidomide Plus R-CHOP (R2CHOP) in Patients with DLBCL Is Associated with a Lower Risk of CNS Relapse: Combined Analysis from Two Phase 2 Studies. Blood, 2016, 128, 3033-3033.	0.6	2
10	Lenalidomide Plus R-CHOP (R2CHOP) in Patients with Follicular Lymphoma: Data from a Phase 1/2 Study. Blood, 2016, 128, 5322-5322.	0.6	0